ro 48-8071 has been researched along with Breast Neoplasms in 4 studies
Ro 48-8071: a cholesterol synthesis inhibitor; structure in first source
Ro 48-8071 : An aromatic ketone that is 2-fluoro-4'-bromobenzophenone in which the hydrogen at position 4 (meta to the fluoro group) is replaced by a 6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy group. An inhibitor of lanosterol synthase.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In most human breast cancers, tumor cell proliferation is estrogen dependent." | 5.40 | Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. ( Aebi, JD; Besch-Williford, C; Cook, MT; Hyder, SM; Liang, Y; Mafuvadze, B; Zou, X, 2014) |
| " We show that both PRIMA-1 and Ro 48-8071, a known potent OSC inhibitor, significantly reduce the viability of BT-474 and T47-D breast cancer cells relative to normal mammary cells." | 3.77 | An inverse docking approach for identifying new potential anti-cancer targets. ( Grinter, SZ; Huang, SY; Hyder, SM; Liang, Y; Zou, X, 2011) |
| "Most hormone-dependent human breast cancers develop resistance to anti-hormone therapy over time." | 1.72 | The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. ( Besch-Williford, C; Hyder, SM; Liang, Y, 2022) |
| "In most human breast cancers, tumor cell proliferation is estrogen dependent." | 1.40 | Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. ( Aebi, JD; Besch-Williford, C; Cook, MT; Hyder, SM; Liang, Y; Mafuvadze, B; Zou, X, 2014) |
| "Treatment of human BT-474 breast cancer cells with RO reduced levels of estrogen-induced PR protein, confirming that RO blocks ERĪ± activity in tumor cells." | 1.40 | Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor. ( Hyder, SM; Liang, Y; Mafuvadze, B, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, Y | 4 |
| Besch-Williford, C | 2 |
| Hyder, SM | 4 |
| Aebi, JD | 1 |
| Mafuvadze, B | 2 |
| Cook, MT | 1 |
| Zou, X | 2 |
| Grinter, SZ | 1 |
| Huang, SY | 1 |
4 other studies available for ro 48-8071 and Breast Neoplasms
| Article | Year |
|---|---|
The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth.
Topics: Animals; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholesterol; Estroge | 2022 |
Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzophenones; Biosynthetic Pathways; Breast Neoplasms; C | 2014 |
Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
Topics: Atorvastatin; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen R | 2014 |
An inverse docking approach for identifying new potential anti-cancer targets.
Topics: Antineoplastic Agents; Aza Compounds; Benzophenones; Breast Neoplasms; Bridged Bicyclo Compounds, He | 2011 |